A comprehensive overview of the neuropsychiatry of Parkinson's disease: A review

Bulletin of the Menninger Clinic

Volumn 81, Issue 1, 2017, Pages 53-105

  Khan, Muhammad Adnan ^a   Quadri, Syed A ^a   Tohid, Hassaan ^b  

^a DOW UNIVERSITY OF HEALTH SCIENCES   (Pakistan)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPINEPHRINE; NORADRENALIN; PRAMIPEXOLE; PSYCHOTROPIC AGENT;

ANXIETY; ANXIETY DISORDER; ARTICLE; CELL INCLUSION; COGNITIVE DEFECT; DEMENTIA; DEPRESSION; ELECTROCONVULSIVE THERAPY; HALLUCINATION; HUMAN; LIMBIC SYSTEM; MAJOR DEPRESSION; MOOD DISORDER; NEUROPSYCHIATRY; PARKINSON DISEASE; PSYCHOSIS; ANXIETY DISORDERS; COGNITION DISORDERS; COMPLICATION; DEPRESSIVE DISORDER, MAJOR; PSYCHOLOGY; PSYCHOTIC DISORDERS;

ANXIETY DISORDERS; COGNITION DISORDERS; DEPRESSIVE DISORDER, MAJOR; HUMANS; PARKINSON DISEASE; PSYCHOTIC DISORDERS;

EID: 85016113864     PISSN: 00259284     EISSN: 19432828     Source Type: Journal    
DOI: 10.1521/bumc.2017.81.1.53     Document Type: Article

References (236)

1. Aarsland, D., Andersen, K., Larsen, J. P., Lolk, A., & Kragh-Sørensen, P. (2003). Prevalence and characteristics of dementia in Parkinson disease: An 8-year prospective study. Archives of Neurology, 60, 387-392.
2. Aarsland, D., Andersen, K., Larsen, J. P., Lolk, A., Nielsen, H., & Kragh-Sørensen, P. (2001). Risk of dementia in Parkinson's disease: A community-based, prospective study. Neurology, 56, 730-736.
3. Aarsland, D., Brønnick, K., Ehrt, U., De Deyn, P. P., Tekin, S., Emre, M., & Cummings, J. L. (2007). Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: Frequency, profile and associated care giver stress. Journal of Neurology, Neurosurgery, and Psychiatry, 78(1), 36-42.
4. Aarsland, D., Bronnick, K., Williams-Gray, C., Weintraub, D., Marder, K., Kulisevsky, J., Emre, M. (2010). Mild cognitive impairment in Parkinson disease: A multicenter pooled analysis. Neurology, 75(12), 1062-1069.
5. Aarsland, D., Hutchinson, M., & Larsen, J. P. (2003). Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. International Journal of Geriatric Psychiatry, 18, 937-941.
6. Aarsland, D., Laake, K., Larsen, J. P., & Janvin, C. (2002). Donepezil for cognitive impairment in Parkinson's disease: A randomised controlled study. Journal of Neurology, Neurosurgery, and Psychiatry, 72, 708-712.
7. Aarsland, D., Larsen, J. P., Cummings, J. L., & Laake, K. (1999). Prevalence and clinical correlates of psychotic symptoms in Parkinson's disease: A community-based study. Archives of Neurology, 56, 595-601.
8. Aarsland, D., Larsen, J. P., Lim, N. G., Janvin, C., Karlsen, K., Tandberg, E., & Cummings, J. L. (1999). Range of neuropsychiatric disturbances in patients with Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry, 67, 492-496.
9. Aarsland, D., Larsen, J. P., Tandberg, E., & Laake, K. (2000). Predictors of nursing home placement in Parkinson's disease: A population-based, prospective study. Journal of the American Geriatric Society, 48(8), 938-942.
10. Aarsland, D., Marsh, L., & Schrag A. (2009). Neuropsychiatric symptoms in Parkinson's disease. Movement Disorders, 24(15), 2175-2186. doi:10:1002/mds: 22589
11. Aarsland, D., Zaccai, J., & Brayne, C. (2005). A systematic review of prevalence studies of dementia in Parkinson's disease. Movement Disorders, 20, 1255-1263.
12. American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: Author.
13. Anderson, K. E. (2004). Behavioral disturbances in Parkinson's disease. Dialogues in Clinical Neuroscience, 6(3), 323-332.
14. Apaydin, H., Ahlskog, J. E., Parisi, J. E., Boeve, B. F., & Dickson, D. W. (2002). Parkinson disease neuropathology: Later-developing dementia and loss of the levodopa response. Archives of Neurology, 59(1), 102-112. doi:10:1001/archneur: 59: 1: 102
15. Arabia, G., Grossardt, B. R., Geda, Y. E., Carlin, J. M., Bower, J. H., Ahlskog, J. E., Rocca, W. A. (2007). Increased risk of depressive and anxiety disorders in relatives of patients with Parkinson disease. Archives of General Psychiatry, 64(12), 1385-1392.
16. Ballard, C., Ziabreva, I., Perry, R., Larsen, J. P., O'Brien, J., McKeith, I., . Aarsland, D. (2006). Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology, 67, 1910-1911.
17. Barone, P., Scarzella, L., Marconi, R., Antonini, A., Morgante, L., Bracco, F., Depression/Parkinson Italian Study Group. (2006). Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: A national multicenter parallel-group randomized study. Journal of Neurology, 253, 601-607.
18. Berg, D., Schweitzer, K. J., Leitner, P., Zimprich, A., Lichtner, P., Belcredi, P., Gasser, T. (2005). Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease. Brain, 128(Pt 12), 3000-3011.
19. Bergman, J., & Lerner, V. (2002). Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease. Clinical Neuropharmacology, 25, 107-110.
20. Boller, F., Mizutani, T., Roessmann, U., & Gambetti, P. (1980). Parkinson disease, dementia, and Alzheimer disease: Clinicopathological correlations. Annals of Neurology, 7, 329-335.
21. Bonifati, V., Fabrizio, E., Cipriani, R., Vanacore, N., & Meco, G. (1994). Buspirone in levodopa-induced dyskinesias. Clinical Neuropharmacology, 17, 73-82.
22. Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O., Breedveld, G. J., Krieger, E., Heutink, P. (2003). Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science, 299, 256-259.
23. Botha, H., & Carr, J. (2012). Attention and visual dysfunction in Parkinson's disease. Parkinsonism and Related Disorders, 18, 742-747.
24. Braak, H., Braak, E., Yilmazer, D., Schultz, C., de Vos, R. A., & Jansen, E. N. (1995). Nigral and extranigral pathology in Parkinson's disease. Journal of Neural Transmission. Supplementum, 46, 15-31.
25. Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H., & Del Tredici, K. (2004). Stages in the development of Parkinson's disease-related pathology. Cell and Tissue Research, 318(1), 121-134.
26. Brooks, R. (1996). EuroQol: The current state of play. Health Policy, 37, 53-72.
27. Bullock, R., & Cameron, A. (2002). Rivastigmine for the treatment of dementia and visual hallucination associated with Parkinson's disease: A case series. Current Medical Research and Opinion, 18, 258-264.
28. Burn, D., Emre, M., McKeith, I., De Deyn, P. P., Aarsland, D., Hsu, C., & Lane, R. (2006). Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Movement Disorders, 21(11), 1899-1907.
29. Caley, C. F., & Friedman, J. H. (1992). Does fluoxetine exacerbate Parkinson' disease? Journal of Clinical Psychiatry, 53, 278-282.
30. Carter, J. H., Stewart, B. J., Archbold, P. G., Inoue, I., Jaglin, J., Lannon, M., Zoog, K. (1998). Living with a person who has Parkinson's disease: The spouse's perspective by stage of disease. Parkinson's Study Group. Movement Disorders, 13, 20-28.
31. Cash, R., Dennis, T., L'Heureux, R., Raisman, R., Javoy-Agid, F., & Scatton, B. (1987). Parkinson's disease and dementia: Norepinephrine and dopamine in locus ceruleus. Neurology, 37, 42-46.
32. Chan, D. K. (2003). The art of treating Parkinson disease in the older patient. Australian Family Physician, 32(11), 927-931.
33. Chaudhuri, K. R., & Schapira, A. H. (2009). Non-motor symptoms of Parkinson's disease: Dopaminergic pathophysiology and treatment. Lancet Neurology, 8(5), 464-474. doi:10:1016/S1474-4422(09)70068-7
34. Chen, P., Kales, H. C., Weintraub, D., Blow, F. C., Jiang, L., Ignacio, R. V., & Mellow, A. M. (2007). Depression in veterans with Parkinson's disease: Frequency, co-morbidity, and healthcare utilization. International Journal of Geriatric Psychiatry, 22(6), 543-548.
35. Cools, R. (2006). Dopaminergic modulation of cognitive function-Implications for l-DOPA treatment in Parkinson's disease. Neuroscience and Biobehavioral Reviews, 30, 1-23. doi:10:1016/j.neubiorev: 2005: 03: 024
36. Cooper, J. A., Sagar, H. J., Doherty, S. M., Jordan, N., Tidswell, P., & Sullivan, E. V. (1992). Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. A follow-up study of untreated patients. Brain, 115, 1701-1725.
37. Cooper, J. A., Sagar, H. J., Jordan, N., Harvey, N. S., & Sullivan, E. V. (1991). Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability. Brain, 114, 2095-2122.
38. Corlett, P. R., Honey, G. D., & Fletcher, P. C. (2007). From prediction error to psychosis: Ketamine as a pharmacological model of delusions. Journal of Psychopharmacology, 21, 238-252.
39. Cummings, J. L. (1988). Intellectual impairment in Parkinson's disease: Clinical, pathologic, and biochemical correlates. Journal of Geriatric Psychiatry and Neurology, 1, 24-36.
40. Cummings, J. L. (1992). Depression and Parkinson's disease: A review. American Journal of Psychiatry, 149, 443-454.
41. de Boer, A. G. E. M., & Wijker, W. (1996). Quality of life in patients with Parkinson's disease: Development of a questionnaire. Journal of Neurology, Neurosurgery, and Psychiatry, 61, 70-74.
42. De Maindreville, A. D., Fénelon, G., & Mahieux, F. (2005). Hallucinations in Parkinson's disease: A follow-up study. Movement Disorders, 20(2), 212-217.
43. de Rijk, M. C., Tzourio, C., Breteler, M. M., Dartigues, J. F., Amaducci, L., Lopez-Pousa, S., Rocca, W. A. (1997). Prevalence of parkinsonism and Parkinson's disease in Europe: The EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's Disease. Journal of Neurology, Neurosurgery, and Psychiatry, 62(1), 10-15.
44. Diederich, N. J., Goetz, C. G., Raman, R., Pappert, E. J., Leurgans, S., & Piery, V. (1998). Poor visual discrimination and visual hallucinations in Parkinson's disease. Clinical Neuropharmacology, 21, 289-295.
45. Dubois, B., & Pillon, B. (1997). Cognitive deficits in Parkinson's disease. Journal of Neurology, 244, 2-8.
46. Dusek, P., Jankovic, J., & Le, W. (2012). Iron dysregulation in movement disorders. Neurobiology of Disease, 46, 1-18. doi:10:1016/j.nbd: 2011: 12: 054
47. Ekman, U., Eriksson, J., Forsgren, L., Mo, S. J., Riklund, K., & Nyberg, L. (2012). Functional brain activity and presynaptic dopamine uptake in patients with Parkinson's disease and mild cognitive impairment: A cross-sectional study. Lancet Neurology, 11, 679-687. doi:10:1016/s1474-4422(12)70138-2
48. Emre, M. (2003). Dementia associated with Parkinson's disease. Lancet Neurology, 2(4), 229-237.
49. Emre, M. (2004). Dementia in Parkinson's disease: Cause and treatment. Current Opinion in Neurology, 17, 399-404.
50. Emre, M., Aarsland, D., Albanese, A., Byrne, E. J., Deuschl, G., De Deyn, P. P., Lane, R. (2004). Rivastigmine for dementia associated with Parkinson's disease. New England Journal of Medicine, 351 (24), 2509-2518.
51. Emre, M., Aarsland, D., Brown, R., Burn, D. J., Duyckaerts, C., Mizuno, Y., DuBois, B. (2007). Clinical diagnostic criteria for dementia associated with Parkinson's disease. Movement Disorders, 22(12), 1689-1707. doi:10:1002/mds: 21507
52. Fabbrini, G., Barbanti, P., Aurilia, C., Pauletti, C., Lenzi, G. L., & Meco, G. (2002). Donepezil in the treatment of hallucinations and delusions in Parkinson's disease. Neurological Sciences, 23, 41-43.
53. Factor, S. A., Feustel, P. J., Friedman, J. H., Cornella, C. L., Goetz, C. G., Kurlan, R., Parkinson Study Group. (2003). Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology, 60(11), 1756-1761.
54. Feldman, B., Chapman, J., & Korczyn, A. D. (2006). Apolipoprotein epsilon4 advances appearance of psychosis in patients with Parkinson's disease. Acta Neurologica Scandinavica, 113(1), 14-17.
55. Fénelon, G., Goetz, C. G., & Karenberg, A. (2006). Hallucinations in Parkinson disease in the prelevodopa era. Neurology, 66, 93-98. doi:10:1212/01.wnl: 0000191325: 31068.c4
56. Fénelon, G., Mahieux, F., Huron, R., & Ziegler, M. (2008). Hallucinations in Parkinson's disease: Prevalence, phenomenology and risk factors. Brain, 123(Pt 4), 733-745.
57. Fernandez, H. H., & Friedman, J. F. (1999). The role of atypical antipsychotics in the treatment of movement disorders. CNS Drugs, 11 (6), 467-483.
58. Findley, L., Eichhorn, T., & Janca, A. (2002). Factors impacting on quality of life in Parkinson's disease: Results from an international survey. Movement Disorders, 17, 60-67.
59. Fogelson, N., Kogan, E., & Korczyn, A. D. (2003). Effects of rivastigmine on the quantitative EEG in demented Parkinsonian patients. Acta Neurologica Scandinavica, 107, 252-255. doi:10:1034/j: 1600-0404: 2003: 00081.x
60. Foltynie, T., Brayne, C. E., Robbins, T. W., & Barker, R. A. (2004). The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain, 127, 550-560.
61. Fournet, N., Moreaud, O., Roulin, J. L., Naegele, B., & Pellat, J. (2000). Working memory functioning in medicated Parkinson's disease patients and the effect of withdrawal of dopaminergic medication. Neuropsychology, 14(2), 247-253.
62. Fox, S. H., Visanji, N. P., Johnston, T. H., Gomez-Ramirez, J., Voon, V., & Brotchie, J. M. (2006). Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease. Archives of Neurology, 63, 1343-1344.
63. Frieling, H., Hillemacher, T., Ziegenbein, M., Neundorfer, B., & Bleich, S. (2007). Treating dopamimetic psychosis in Parkinson's disease: Structured review and meta-analysis. European Neuropsychopharmacology, 17(3), 165-171.
64. Fukunishi, I., Hosokawa, K., & Ozaki, S. (1991). Depression antedating the onset of Parkinson's disease. Japanese Journal of Psychiatry and Neurology, 45, 7-11.
65. Garcia-Garcia, D., Clavero, P., Gasca Salas, C., Lamet, I., Arbizu, J., Gonzalez- Redondo, R., . Rodriguez-Oroz, M. C. (2012). Posterior parietooccipital hypometabolism may differentiate mild cognitive impairment from dementia in Parkinson's disease. European Journal of Nuclear Medicine and Molecular Imaging, 39, 1767-1777. doi:10:1007/s00259-012-2198-2195
66. Gaspar, P., & Gray, F. (1984). Dementia in idiopathic Parkinson's disease. A neuropathological study of 32 cases. Acta Neuropathologica (Berlin), 64, 43-52.
67. Giladi, N., Shabtai, H., & Gurevich, T. (2003). Rivastigmine (Exelon) for dementia in patients with Parkinson's disease. Acta Neurologica Scandinavica, 108, 368-373. doi:10:1034/j: 1600-0404: 2003: 00211.x
68. Giladi, N., Treves, T. A., Paleacu, D., Shabtai, H., Orlov, Y., Kandinov, B., Korczyn, A. D. (2000). Risk factors for dementia, depression, and psychosis in longstanding Parkinson's disease. Journal of Neural Transmission, 107(1), 59-71. doi:10:1007/s007020050005
69. Goetz, C. G., Fan, W., Leurgans, S., Bernard, B., & Stebbins, G. T. (2006). The malignant course of "benign hallucinations" in Parkinson disease. Archives of Neurology, 63, 713-716.
70. Goetz, C. G., & Stebbins, G. T. (1993). Risk factors for nursing home placement in advanced Parkinson's disease. Neurology, 43, 2227-2229.
71. Goldman, J. G., & Litvan, I. (2011). Mild cognitive impairment in Parkinson's disease. Minerva Medica, 102(6), 441-459.
72. Gotham, A. M., Brown, R. G., & Marsden, C. D. (1986). Depression in Parkinson's disease: A quantitative and qualitative analysis. Journal of Neurology, Neurosurgery, and Psychiatry, 49, 381-389.
73. Gotham, A. M., Brown, R. G., & Marsden, C. D. (1988). "Frontal" cognitive function in patients with Parkinson's disease "on" and "off" levodopa. Brain, 111, 299-321.
74. Grace, A. A. (2010). Dopamine system dysregulation by the ventral subiculum as the common pathophysiological basis for schizophrenia psychosis, psychostimulant abuse, and stress. Neurotoxicity Research, 18, 367-376. doi:10:1007/s12640-010-9154-9156
75. Graham, J. M., Grunewald, R. A., & Sagar, H. J. (1997). Hallucinosis in idiopathic Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry, 63(4), 434-440.
76. Hanagasi, H. A., & Emre, M. (2002). Management of the neuropsychiatric and cognitive symptoms in Parkinson's disease. Practical Neurology, 2, 94-102.
77. Hanagasi, H. A., Gurvit, H., Unsalan, P., Horozoglu, H., Tuncer, N., Feyzioglu, A., Emre, M. (2011). The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: A randomized, double-blind, placebo-controlled, multicenter study. Movement Disorders, 26(10), 1851-1858. doi:10:1002/mds: 23738
78. Harding, A. J., Broe, G. A., & Halliday, G. M. (2002). Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain, 125(2), 391-403.
79. Hely, M. A., Morris, J. G., Reid, W. G., & Trafficante, R. (2005). Sydney Multicenter Study of Parkinson's disease: Non-L-dopa-responsive problems dominate at 15 years. Movement Disorders, 20, 190-199.
80. Holdorff, B. (2002). Friedrich Heinrich Lewy (1885-1950) and his work. Journal of the History of the Neurosciences, 11(1), 19-28.
81. Holroyd, S., Currie, L., & Wooten, G. F. (2001). Prospective study of hallucinations and delusions in Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry, 70, 734-738.
82. Hornykiewicz, O. (1975). Parkinson's disease and its chemotherapy. Biochemical Pharmacology, 24(10), 1061-1065.
83. Hornykiewicz, O. (2006). The discovery of dopamine deficiency in the parkinsonian brain. Journal of Neural Transmission. Supplementum, (70), 9-15.
84. Howes, O. D., Kambeitz, J., Kim, E., Stahl, D., Slifstein, M., Abi-Dargham, A., & Kapur, S. (2012). The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Archives of General Psychiatry, 69, 776-786.
85. Huber, S. J., Paulson, G. W., & Shuttleworth, E. C. (1988). Depression in Parkinson's disease. Neuropsychiatry, Neuropsychology and Behavioral Neurology, 1, 47-51.
86. Huber, S. J., Shuttleworth, E. C., & Freidenberg, D. L. (1989). Neuropsychological differences between the dementias of Alzheimer's and Parkinson's diseases. Archives of Neurology, 46, 1287-1291.
87. Hughes, T. A., Ross, H. F., Mindham, R. H., & Spokes, E. G. (2004). Mortality in Parkinson's disease and its association with dementia and depression. Acta Neurologica Scandinavica, 110(2), 118-123.
88. Hughes, T. A., Ross, H. F., Musa, S., Bhattacherjee, S., Nathan, R. N., Mindham, R. H., & Spokes, E. G. (2000). A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease. Neurology, 54, 1596-1602.
89. Hurtig, H. I., Trojanowski, J. Q., Galvin, J., Ewbank, D., Schmidt, M. L., Lee, V. M., Arnold, S. E. (2000). Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology, 54, 1916-1921.
90. Hurwitz, T. A., Calne, D. B., & Waterman, K. (1988). Treatment of dopamimetic psychosis in Parkinson's disease with electroconvulsive therapy. Canadian Journal of Neurological Sciences, 15(1), 32-34. doi:10:1017/S0317167100027141
91. Hutchinson, M., & Fazzini, E. (1996). Cholinesterase inhibition in Parkinson's disease. [letter]. Journal of Neurology, Neurosurgery, and Psychiatry, 61, 324-325.
92. Iruela, L. M., Ibañez-Rojo, V., Palanca, I., & Caballero, L. (1992). Anxiety disorders and Parkinson's disease. American Journal of Psychiatry, 149, 719-720.
93. Jankovic, J. (2008). Parkinson's disease: Clinical features and diagnosis. Journal of Neurology, Neurosurgery, and Psychiatry, 79(4), 368-376. doi:10:1136/jnnp: 2007: 131045
94. Janvin, C., Aarsland, D., Larsen, J. P., & Hugdahl, K. (2003). Neuropsychological profile of patients with Parkinson's disease without dementia. Dementia and Geriatric Cognitive Disorders, 15(3), 126-131.
95. Janvin, C. C., Larsen, J. P., Aarsland, D., & Hugdahl, K. (2006). Subtypes of mild cognitive impairment in Parkinson's disease: Progression to dementia. Movement Disorders, 21(9), 1343-1349.
96. Jellinger, K. A. (1991). Pathology of Parkinson's disease. Molecular and Chemical Neuropathology, 14(3), 153-197. doi:10:1007/BF03159935
97. Jellinger, K. A., & Paulus, W. (1992). Clinico-pathological correlations in Parkinson's disease. Clinical Neurology and Neurosurgery, 94(Suppl.), S86-S88.
98. Jenner, P., & Olanow, C. W. (1996). Oxidative stress and the pathogenesis of Parkinson's disease. Neurology, 47(6 Suppl. 3), S161-S170.
99. Jiménez-Jiménez, F. J., Tejeiro, J., Martínez-Junquera, G., Cabrera-Valdivia, F., Alarcón, J., & García-Albea, G. (1994). Parkinsonism exacerbated by paroxetine. [letter]. Neurology, 44, 2406.
100. Juncos, J. L. (1999). Management of psychotic aspects of Parkinson's disease. Journal of Clinical Psychiatry, 60, 42-53.
101. Kaplan, R. M., Bush, J. W., & Berry, C. C. (1976). Health status: Types of validity and the Index of Well-Being. Health Services Research, 11, 478-507.
102. Kish, S. J., Shannak, K., & Hornykiewicz, O. (1988). Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Patho-physiologic and clinical implications. New England Journal of Medicine, 318, 876-880. doi:10:1056/nejm198804073181402
103. Kuopio, A. M., Marttila, R. J., Helenius, H., Toivonen, M., & Rinne, U. K. (2000). The quality of life in Parkinson's disease. Movement Disorders, 15, 216-223.
104. Lauterbach, E. C. (1993). The locus ceruleus and anxiety disorders in demented and nondemented familial parkinsonism. [letter]. American Journal of Psychiatry, 150, 994.
105. Lauterbach, E. C., & Duvoisin, R. C. (1992). Anxiety disorders in familial parkinsonism. [letter]. American Journal of Psychiatry, 148, 274.
106. Lee, J. E., Cho, K. H., Kim, M., Sohn, Y. H., & Lee, P. H. (2012). The pattern of cortical atrophy in Parkinson's disease with mild cognitive impairment according to the timing of cognitive dysfunction. Journal of Neurology, 259, 469-473. doi:10:1007/s00415-011-6203-x
107. Leentjens, A. F. (2004). Depression in Parkinson's disease: Conceptual issues and clinical challenges. Journal of Geriatric Psychiatry and Neurology, 17(3), 120-126.
108. Leentjens, A. F., Dujardin, K., Marsh, L., Martinez-Martin, P., Richard, I. H., Starkstein, S. E., Goetz, C. G. (2008). Anxiety rating scales in Parkinson's disease: Critique and recommendations. Movement Disorders, 23(14), 2015-2025. doi:10:1002/mds: 22233
109. Lemke, M. R. (2007). Dopaminagonisten als Antidepressiva: Experimentelle und klinische Befunde [Antidepressant effects of dopamine agonists: Experimental and clinical findings]. Der Nervenarzt, 78, 31-38. doi:10:1007/s00115-006-2104-2100
110. Lemke, M. R., Brecht, H. M., Koester, J., Kraus, P. H., & Reichmann, H. (2005). Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole. Journal of Neuropsychiatry and Clinical Neurosciences, 17, 214-220.
111. Lemke, M. R., Brecht, H. M., Koester, J., & Reichmann, H. (2006). Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease. Journal of Neurological Sciences, 248, 266-270.
112. Leroy, E., Boyer, R., Auburger, G., Leube, B., Ulm, G., Mezey, E., . Polymerpoulos, M. H. (1998). The ubiquitin pathway in Parkinson's disease. Nature, 395, 451-452.
113. Levin, B. E., & Katzen, H. L. (1995). Early cognitive changes and nondementing behavioral abnormalities in Parkinson's disease. Advances in Neurology, 65, 85-95.
114. Levy, G. (2007). The relationship of Parkinson disease with aging. Archives of Neurology, 64, 1242-1246. doi:10:1001/archneur: 64: 9: 1242
115. Lew, M. (2007). Overview of Parkinson's disease. Pharmacotherapy, 27(12 Pt 2), 155S-160S.
116. Lieberman, A. (1998). Managing the neuropsychiatric symptoms of PD. Neurology, 50(Suppl. 6), S27-S32.
117. Litvan, I., Goldman, J. G., Troster, A. I., Schmand, B. A., Weintraub, D., Petersen, R. C., Emre, M. (2012). Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force Guidelines. Movement Disorders, 27, 349-356. doi:10:1002/mds: 24893
118. Litvan, I., Mohr, E., Williams, J., Gomez, C., & Chase, T. N. (1991). Differential memory and executive functions in demented patients with Parkinson's and Alzheimer's disease. Journal of Neurology, Neurosurgery, and Psychiatry, 54, 25-29.
119. Ludwig, C. L., Weinberger, D. R., Bruno, G., Gillespie, M., Bakker, K., LeWitt, P. A., & Chase, T. N. (1986). Buspirone, Parkinson's disease and the locus ceruleus. Clinical Neuropharmacology, 9, 373-378.
120. Mann, D. M., Yates, P O., & Hawkes, J. (1983). The pathology of the human locus ceruleus. Clinical Neuropathology, 2, 1-7.
121. Manzoni, C., & Lewis, P. A. (2013). Dysfunction of the autophagy/lysosomal degradation pathway is a shared feature of the genetic synucleinopathies. FASEB Journal, 27(9), 3424-3429. doi:10:1096/fj: 12-223842
122. Marder, K. (2010). Cognitive impairment and dementia in Parkinson's disease. Movement Disorders, 25(Suppl. 1), S110-S116.
123. Marder, K., Leung, D., Tang, M., Bell, K., Dooneief, G., Cote, L., Mayeux, R. (1991). Are demented patients with Parkinson's disease accurately reflected in prevalence surveys? A survival analysis. Neurology, 41, 1240-1243.
124. Marder, K., Tang, M. X., Cote, L., Stern, Y., & Mayeux, R. (1995). The frequency and associated risk factors for dementia in patients with Parkinson's disease. Archives of Neurology, 52, 695-701.
125. Maricle, R. A., Nutt, J. G., Valentine, R. J., & Carter, J. H. (1995). Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease: A double-blind, placebo-controlled study. Neurology, 45(9), 1757-1760.
126. Marinus, J., Leentjens, A. F., Visser, M., Stiggelbout, A. M., & van Hilten, J. J. (2002). Evaluation of the Hospital Anxiety and Depression Scale in patients with Parkinson's disease. Clinical Neuropharmacology, 25, 318-324.
127. Marinus, J., Visser, M., Verwey, N. A., Verhey, F. R., Middelkoop, H. A., Stiggelbout, A. M., & van Hilten, J. J. (2003). Assessment of cognition in Parkinson's disease. Neurology, 61, 1222-1228.
128. Marsden, C. D. (1994). Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry, 57, 672-681.
129. Marsh, L. (2000a). Anxiety disorders in Parkinson's disease. International Review of Psychiatry, 12(4), 307-318. doi:10:1080/09540260020002532
130. Marsh, L. (2000b). Neuropsychiatric aspects of Parkinson's disease. Psychosomatics, 41, 15-23.
131. Mayeux, R., Stern, Y., Rosen, J., & Leventhal, J. (1981). Depression, intellectual impairment, and Parkinson disease. Neurology, 31, 645-650.
132. Marsh, L., Biglan, K., Gerstenhaber, M., & Williams, J. R. (2009). Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: A pilot open-label study. Movement Disorders, 24(2), 277-282.
133. Marsh, L., McDonald, W. M., Cummings, J., & Ravina, B. (2006). Provisional diagnostic criteria for depression in Parkinson's disease: Report of an NINDS/NIMH Work Group. Movement Disorders, 21, 148-158.
134. Mayeux, R. (1990). The "serotonin hypothesis" for depression in Parkinson's disease. Advances in Neurology, 53, 163-166.
135. McDonald, W. M., Richard, I. H., & DeLong, M. R. (2003). Prevalence, etiology, and treatment of depression in Parkinson's disease. Biological Psychiatry, 54, 363-375.
136. Mehndiratta, M., Garg, R. K., & Pandey, S. (2011). Nonmotor symptom complex of Parkinson's disease-An under-recognized entity. Journal of the Association of Physicians of India, 59, 302-308, 313.
137. Melzer, T. R., Watts, R., MacAskill, M. R., Pitcher, T. L., Livingston, L., Keenan, R. J., . Anderson, T. J. (2012). Grey matter atrophy in cognitively impaired Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry, 83, 188-194. doi:10:1136/jnnp-2011-300828
138. Menza, M., Dobkin, R. D., Marin, H., Mark, M. H., Gara, M., Buyske, S., Dicke, A. (2009). A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology, 72(10), 886-892. doi:10:1212/01.wnl: 0000336340: 89821.b3
139. Menza, M. A., Robertson-Hoffman, D. E., & Bonapace, A. S. (1993). Parkinson's disease and anxiety: Comorbidity with depression. Biological Psychiatry, 34(7), 465-470.
140. Moellentine, C., Rummans, T., Ahlskog, J. E., Harmsen, W. S., Suman, J. V., O'Connor, M. K., Pileggi, T. (1998). Effectiveness of ECT in patients with parkinsonism. Journal of Neuropsychiatry and Clinical Neurosciences, 10(2), 187-193.
141. Montastruc, J.-L., Fabre, N., Blin, O., Senard, J.-M., Rascol, O., & Rascol, A. (1995). Does fluoxetine aggravate Parkinson's disease? A pilot prospective study. Movement Disorders, 10, 355-357. doi:10:1002/mds: 870100325
142. Morgante, L., Epifanio, A., Spina, E., Zappia, M., Di Rosa, A. E., Marconi, R., Quattrone, A. (2004). Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clinical Neuropharmacology, 27(4), 153-156.
143. Moriarty, J. (2008). Suicide following deep brain stimulation for Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry, 79(8), 851. doi:10:1136/jnnp: 2008: 151134
144. Moustafa, A. A., & Poletti, M. (2013). Neural and behavioral substrates of subtypes of Parkinson's disease. Frontiers in Systems Neuroscience, 7, 117. doi:10:3389/fnsys: 2013: 00117
145. Myslobodsky, M., Lalonde, F. M., & Hicks, L. (2001). Are patients with Parkinson's disease suicidal? Journal of Geriatric Psychiatry and Neurology, 14, 120-124.
146. Nagano-Saito, A., Habak, C., Mejía-Constaín, B., Degroot, C., Monetta, L., Jubault, T., Monchi, O. (2013). Effect of mild cognitive impairment on the patterns of neural activity in early Parkinson's disease. Neurobiology of Aging, 35, 223-231. doi:10:1016/j.neurobiolaging: 2013: 06: 025
147. Nakano, I., & Hirano, A. (1984). Parkinson's disease: Neuron loss in the nucleus basalis without concomitant Alzheimer's disease. Annals of Neurology, 15, 415-418.
148. National Parkinson Foundation. (n. D.). PD fact sheet. Retrieved from http://www.parkinson.org/sites/default/files/Parkinsons%20Dis-ease%20Fact%20Sheet.pdf
149. National Parkinson Foundation. (2012). Depression drives quality of life in Parkinson's: NPF releases new report to the community. Parkinson Report, 23(3), 1-2. Retrieved from http://www.parkinson.org/sites/default/files/Parkinson%20Report%20-%20Fall-Winter%202012.pdf
150. Nazem, S., Siderowf, A. D., Duda, J. E., Brown, G. K., Ten Have, T., Stern, M. B., & Weintraub, D. (2008). Suicidal and death ideation in Parkinson's disease. Movement Disorders, 23(11), 1573-1579.
151. NIH Senior Health. (n. D.). Parkinson's disease. Retrieved from http://nih-seniorhealth.gov/parkinsonsdisease/whatisparkinsonsdisease/01.html
152. Nissenbaum, H., Quinn, N. P., Brown, R. G., Toone, B., Gotham, A. M., & Marsden, C. D. (1987). Mood swings associated with the 'on-off' phenomenon in Parkinson's disease. Psychological Medicine, 17(4), 899-904.
153. Nuti, A., Ceravolo, R., Piccinni, A., Dell'Agnello, G., Bellini, G., Gambaccini, E., Bonuccelli, U. (2004). Psychiatric comorbidity in a population of Parkinson's disease patients. European Journal of Neurology, 11(5), 315-320.
154. Okun, M. S., & Watts, R. L. (2002). Depression associated with Parkinson's disease: Clinical features and treatment. Neurology, 58, S63-S70.
155. Olanow, C. W., & Koller, W. C. (1998). An algorithm (decision tree) for the management of Parkinson's disease: Treatment guidelines. Neurology, 50(Suppl. 3), S1- S57.
156. Onofrj, M., Thomas, A., & Bonanni, L. (2007). New approaches to understanding hallucinations in Parkinson's disease: Phenomenology and possible origins. Expert Review of Neurotherapeutics, 7(12), 1731-1750.
157. Opara, J. A., Brola, W., Leonardi, M., & Błaszczyk, B. (2012). Quality of life in Parkinson's disease. Journal of Medicine and Life, 5(4), 375-381.
158. Ozer, F., Meral, H., Aydin, B., Hanoglu, L., Aydemir, T., & Oral, T. (2005). Electroconvulsive therapy in drug induced psychiatric states and neuroleptic malignant syndrome. Journal of ECT, 21(2), 125-127.
159. Pagonabarraga, J., Kulisevsky, J., Llebaria, G., Garcia-Sanchez, C., Pascual-Sedano, B., & Gironell, A. (2008). Parkinson's Disease-Cognitive Rating Scale: A new cognitive scale specific for Parkinson's disease. Movement Disorders, 23(7), 998-1005.
160. Pandey, S., Singh, B., Verma, R., & Mahdi, A. A. (2013). Current understanding of Parkinson disease. International Journal of Pharmacotherapy, 3(2), 70-79.
161. Papapetropoulos, S. (2006). Drug-induced psychosis in Parkinson disease: Phenomenology and correlations among psychosis rating instruments. Clinical Neuropharmacology, 29, 59.
162. Papapetropoulos, S., Argyriou, A. A., & Ellul, J. (2005). Factors associated with drug-induced visual hallucinations in Parkinson's disease. Journal of Neurology, 252(10), 1223-1228.
163. Papapetropoulos, S., Farrer, M. J., Stone, J. T., Milkovic, N. M., Ross, O. A., Calvo, L., Mash, D. C. (2007). Phenotypic associations of tau and ApoE in Parkinson's disease. Neuroscience Letters, 414, 141-144.
164. Papapetropoulos, S., McCorquodale, D. S., Gonzalez, J., Jean-Gilles, L., & Mash, D. C. (2006). Cortical and amygdalar Lewy body burden in Parkinson's disease patients with visual hallucinations. Parkinsonism and Related Disorders, 12, 253-256.
165. Pappatà, S., Santangelo, G., Aarsland, D., Vicidomini, C., Longo, K., Bronnick, K., Barone, P. (2011). Mild cognitive impairment in drug-naive patients with PD is associated with cerebral hypometabolism. Neurology, 77, 1357-1362. doi:10:1212/wnl:0b013e3182315259
166. Pappert, E. J., Goetz, C. G., Niederman, F. G., Raman, R., & Leurgans, S. (1999). Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease. Movement Disorders, 14, 117-121.
167. París, A. P., Saleta, H. G., de la Cruz Crespo Maraver, M., Silvestre, E., Freixa, M. G., Torrellas, C. P., Bayés, A. R. (2011). Blind randomized controlled study of the efficacy of cognitive training in Parkinson's disease. Movement Disorders, 26(7), 1251-1258. doi:10:1002/mds: 23688
168. Parkinson's Disease Foundation. (n. D.). Statistics on Parkinson's. Retrieved from http://www.pdf.org/en/parkinson_statistics
169. Pascual-Sedano, B., Kulisevsky, J., Barbanoj, M., García-Sánchez, C., Campolongo, A., Gironell, A., Gich, I. (2008). Levodopa and executive performance in Parkinson's disease: A randomized study. Journal of the International Neuropsychological Society, 14(5), 832-841. doi:10:1017/S1355617708081010
170. Paulus, W., & Jellinger, K. (1991). The neuropathologic basis of different clinical subgroups of Parkinson's disease. Journal of Neuropathology and Experimental Neurology, 50(6), 743-755.
171. Perry, E. K., Curtis, M., Dick, D. J., Candy, J. M., Atack, J. R., Bloxham, C. A., Perry, R. H. (1985). Cholinergic correlates of cognitive impairment in Parkinson's disease: Comparisons with Alzheimer's disease. Journal of Neurology, Neurosurgery, and Psychiatry, 48, 413-421.
172. Perry, E. K., Irving, D., Kerwin, J. M., McKeith, I. G., Thompson, P., Collerton, D., Perry, R. H. (1993). Cholinergic transmitter and neurotrophic activities in Lewy body dementia: Similarity to Parkinson's and distinction from Alzheimer disease. Alzheimer Disease and Associated Disorders, 7, 69-79.
173. Perry, R. H., Perry, E. K., Smith, C. J., Xuereb, J. H., Irving, D., Whitford, C. A., Cross, A. J. (1987). Cortical neuropathological and neurochemical substrates of Alzheimer's and Parkinson's diseases. Journal of Neural Transmission Supplementum 24, 131-136.
174. Peyser, C. E., Naimark, D., Zuniga, R., & Jeste, D. V. (1998). Psychoses in Parkinson's disease. Seminars in Clinical Neuropsychiatry, 3, 41-50.
175. Pillon, B., Boller, F., Levy, R., & Dubois, B. (2001). Cognitive deficits and dementia in Parkinson's disease. In F. Boller & S. Cappa (Eds.), Handbook of neuropsychology (2nd ed.; pp. 311-371). Amsterdam, The Netherlands: Elsevier Science.
176. Poewe, W. (2008). Non-motor symptoms in Parkinson's disease. European Journal of Neurology, 15(Suppl. 1), 14-20. doi:10:1111/j: 1468-1331: 2008: 02056.x
177. Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., . Nussbaum, R. L. (1997). Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science, 276, 2045-2047.
178. Ravina, B., Marder, K., Fernandez, H. H., Friedman, J. H., McDonald, W., Murphy, D., Goetz, C. (2007). Diagnostic criteria for psychosis in Parkinson's disease: Report of an NINDS/NIMH work group. Movement Disorders, 22(8), 1061-1068.
179. Reading, P. J., Luce, A. K., & McKeith, I. G. (2001). Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: Preliminary findings from an open trial. Movement Disorders, 16, 1171-1174.
180. Reijnders, J. S., Ehrt, U., Weber, W. E., Aarsland, D., & Leentjens, A. F. (2008). A systematic review of prevalence studies of depression in Parkinson's disease. Movement Disorders, 23(2), 183-189.
181. Rektorová, I., Rektor, I., Bares, M., Dostál, V., Ehler, E., Fanfrdlová, Z., Velísková, A. (2003). Pramipexole and pergolide in the treatment of depression in Parkinson's disease: A national multicentre prospective randomized study. European Journal of Neurology, 10, 399-406.
182. Remy, P., Doder, M., Lees, A., Turjanski, N., & Brooks, D. (2005). Depression in Parkinson's disease: Loss of dopamine and noradrenaline innervation in the limbic system. Brain, 128(Pt 6), 1314-1322.
183. Richard, I. H. (2005). Anxiety disorders in Parkinson's disease. Advances in Neurology, 96, 42-55.
184. Richard, I. H., & Kurlan, R. (1997). A survey of antidepressant drug use in Parkinson's disease. Parkinson Study Group. Neurology, 49, 1168-1170.
185. Richard, I. H., Schiffer, R. B., & Kurlan, R. (1996). Anxiety and Parkinson's disease. Journal of Neuropsychiatry and Clinical Neurosciences, 8, 383-392.
186. Rondot, P., de Recondo, J., Coignet, A., & Ziegler, M. (1984). Mental disorders in Parkinson's disease after treatment with L-DOPA. Advances in Neurology, 40, 259-269.
187. Ruberg, M., & Agid, Y. (1988). Dementia in Parkinson's disease. In L. Iversen, S. Iversen, & S. Snyder (Eds.), Handbook of psychopharmacology (pp. 157-206). New York, NY: Plenum Press.
188. Sanchez-Ramos, J. R., Ortoll, R., & Paulson, G. W. (1996). Visual hallucinations associated with Parkinson disease. Archives of Neurology, 53(12), 1265-1268.
189. Sano, M., Stern, Y., Williams, J., Coté, L., Rosenstein, R., & Mayeux, R. (1989). Coexisting dementia and depression in Parkinson's disease. Archives of Neurology, 46, 1284-1286.
190. Scatton, B., Javoy-Agid, F., Rouquier, L., Dubois, B., & Agid, Y. (1983). Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Research, 275, 321-328.
191. Schapira, A. H. (2008). Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurology, 7, 97-109. doi:10:1016/s1474-4422(07)70327-7
192. Schiffer, R. B., Kurlan, R., & Rubin, A. (1988). Evidence for atypical depression in Parkinson's disease. American Journal of Psychiatry, 145, 1020-1022.
193. Schrag, A. (2006). Quality of life and depression in Parkinson's disease. Journal of the Neurological Sciences, 248(1-2), 151-157. doi:10:1016/j.jns: 2006: 05: 030
194. Schrag, A., Jahanshahi, M., & Quinn, N. (2000). What contributes to quality of life in patients with Parkinson's disease? Journal of Neurology, Neurosurgery, and Psychiatry, 69, 308-312.
195. Schrag, A., Jahanshahi, M., & Quinn, N. P. (2001). What contributes to depression in Parkinson's disease? Psychological Medicine, 31, 65-73.
196. Serrano-Dueñas, M. (2002). Dosis bajas de amitriptilina frente a dosis bajas de fluoxetina en el tratamiento de la depresión de enfermos con enfermedad de Parkinson [A comparison between low doses of amitriptyline and low doses of fluoxetin used in the control of depression in patients suffering from Parkinson's disease]. Revista de Neurologia, 35(11), 1010-1014.
197. Setó-Salvia, N., Clarimón, J., Pagonabarraga, J., Pascual-Sedano, B., Campolongo, A., Combarros, O., Martínez-Corral, M. (2011). Dementia risk in Parkinson disease: Disentangling the role of MAPT haplotypes. Archives of Neurology, 68(3), 359-364.
198. Shimura, H., Schlossmacher, M. G., Hattori, N., Frosch, M. P., Trockenbacher, A., Schneider, R., Selkoe, D. J. (2001). Ubiquitination of a new form of alphasynuclein by parkin from human brain: Implications for Parkinson's disease. Science, 293, 263-269.
199. Siemers, E. R., Shekhar, A., Quaid, K., & Dickson, H. (1993). Anxiety and motor performance in Parkinson's disease. Movement Disorders, 8(4), 501-506.
200. Simuni, T., & Sethi, K. (2008). Nonmotor manifestations of Parkinson's disease. Annals of Neurology, 64(Suppl. 2), S65-S80. doi:10:1002/ana: 21472
201. Sinforiani, E., Banchieri, L., Zucchella, C., Pacchetti, C., & Sandrini, G. (2004). Cognitive rehabilitation in Parkinson's disease. Archives of Gerontology and Geriatrics. Supplement, (9), 387-391.
202. Song, S. K., Lee, J. E., Park, H. J., Sohn, Y. H., Lee, J. D., & Lee, P. H. (2011). The pattern of cortical atrophy in patients with Parkinson's disease according to cognitive status. Movement Disorders, 26, 289-296. doi:10:1002/mds: 23477
203. Soulas, T., Gurruchaga, J. M., Palfi, S., Cesaro, P., Nguyen, J. P., & Fénelon, G. (2008). Attempted and completed suicides after subthalamic nucleus stimulation for Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry, 79(8), 952-954. doi:10:1136/jnnp: 2007: 130583.
204. Starkstein, S. E., & Leentjens, A. F. G. (2008). The nosological position of apathy in clinical practice. Journal of Neurology, Neurosurgery, and Psychiatry, 79, 1088-1092.
205. Stein, M. B., Heuser, I. J., Juncos, J. L., & Uhde, T. W. (1990). Anxiety disorders in patients with Parkinson's disease. American Journal of Psychiatry, 147(2), 217-220.
206. Steur, E. N. (1993). Increase of Parkinson disability after fluoxetine medication. Neurology, 43, 211-213.
207. Summerfield, C., Junqué, C., Tolosa, E., Salgado-Pineda, P., Gómez-Ansón, B., Martí, M. J., . Mercader, J. (2005). Structural brain changes in Parkinson disease with dementia: A voxel-based morphometry study. Archives of Neurology, 62, 281-285. doi:10:1001/archneur: 62: 2: 281
208. Surany-Cadotte, B. E., Nesteros, J. N., Nair, N. P., Lal, S., & Gauthier, S. (1985). Parkinsonism induced by high doses of diazepam. Biological Psychiatry, 20, 455-457.
209. Torack, R. M., & Morris, J. C. (1988). The association of ventral tegmental area histopathology with adult dementia. Archives of Neurology, 45(5), 497-501.
210. Twelves, D., Perkins, K. S., & Counsell, C. (2003). Systematic review of incidence studies of Parkinson's disease. Movement Disorders, 18(1), 19-31.
211. Van Den Eeden, S. K., Tanner, C. M., Bernstein, A. L., Fross, R. D., Leimpeter, A., Bloch, D. A., & Nelson, L. M. (2003). Incidence of Parkinson's disease: Variation by age, gender, and race/ethnicity. American Journal of Epidemiology, 157(11), 1015-1022.
212. van der Wurff, F. B., Stek, M. L., Hoogendijk, W. J., & Beekman, A. T. (2003). The efficacy and safety of ECT in depressed older adults: A literature review. International Journal of Geriatric Psychiatry, 18(10), 894-904.
213. Vázquez, A., Jiménez-Jiménez, F. J., García-Ruiz, P., & García-Urra, D. (1993). "Panic attacks" in Parkinson's disease. A long-term complication of levodopa therapy. Acta Neurologica Scandinavica, 87, 14-18.
214. Veazey, C., Aki, S. O. E., Cook, K. F., Lai, E. C., & Kunik, M. E. (2005). Prevalence and treatment of depression in Parkinson's disease. Journal of Neuropsychiatry and Clinical Neurosciences, 17, 310-323.
215. Vieira, R. T., Caixeta, L., Machado, S., & Caixeta, M. (2011). Dementia in Parkinson's disease: A clinical review. American Journal of Neuroscience, 2(1), 35-47. doi:10:3844/amjnsp: 2011: 35: 47
216. von Campenhausen, S., Bornschein, B., Wick, R., Bötzel, K., Sampaio, C., Poewe, W., Dodel, R. (2005). Prevalence and incidence of Parkinson's disease in Europe. European Neuropsychopharmacology, 15(4), 473-490.
217. Voon, V., Krack, P., Lang, A. E., Lozano, A. M., Dujardin, K., Schupbach, M., Moro, E. (2008). A multicentre study on suicide out-comes following subthalamic stimulation for Parkinson's disease. Brain, 131 (Pt. 10), 2720-2728.
218. Walsh, K., & Bennett, G. (2001). Parkinson's disease and anxiety. Postgraduate Medical Journal, 77, 89-93.
219. Weintraub, D. (2004). Diagnosing and treating depression in patients with Parkinson's disease. Psychiatric Annals, 34(4), 299-304.
220. Weintraub, D., Doshi, J., Koka, D., Davatzikos, C., Siderowf, A. D., Duda, J. E., Clark, C. M. (2011). Neurodegeneration across stages of cognitive decline in Parkinson disease. Archives of Neurology, 68, 1562-1568. doi:10:1001/archneurol: 2011: 725
221. Weintraub, D., Moberg, P. J., Duda, J. E., Katz, I. R., & Stern, M. B. (2003). Recognition and treatment of depression in Parkinson's disease. Journal of Geriatric Psychiatry and Neurology, 16(3), 178-183.
222. Weintraub, D., Morales, K. H., Moberg, P. J., Bilker, W. B., Balderston, C., Duda, J. E., Stern, M. B. (2005). Antidepressant studies in Parkinson's disease: A review and meta-analysis. Movement Disorders, 20, 1161-1169.
223. Werber, E. A., & Rabey, J. M. (2001). The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia. Journal of Neural Transmission, 108, 1319-1325.
224. Williams-Gray, C. H., Foltynie, T., Brayne, C. E., Robbins, T. W., & Barker, R. A. (2007). Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain, 130(Pt. 7), 1787-1798.
225. Williams-Gray, C. H., Goris, A., Saiki, M., Foltynie, T., Compston, D. A., Sawcer, S. J., & Barker, R. A. (2009). Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease. Journal of Neurology, 256(3), 493-498.
226. Williams-Gray, C. H., Mason, S. L., Evans, J. R., Foltynie, T., Brayne, C., Robbins, T. W., & Barker, R. A. (2013). The CamPaIGN study of Parkinson's disease: 10-Year outlook in an incident population-based cohort. Journal of Neurology, Neurosurgery, and Psychiatry, 84, 1258-1264. doi:10:1136/jnnp-2013-305277
227. Wint, D. P., Okun, M. S., & Fernandez, H. H. (2004). Psychosis in Parkinson's disease. Journal of Geriatric Psychiatry and Neurology, 17(3), 127-136. doi:10:1177/0891988704267457
228. Witjas, T., Kaphan, E., Azulay, J. P., Blin, O., Ceccaldi, M., Pouget, J., Chérif, A. A. (2002). Nonmotor fluctuations in Parkinson's disease: Frequent and disabling. Neurology, 59(3), 408-413.
229. Wolters, E. C. (1999). Dopaminomimetic psychosis in Parkinson's disease patients. Neurology, 52(Suppl. 3), S10-S13.
230. Wolters, E. C. (2001). Intrinsic and extrinsic psychosis in Parkinson's disease. Journal of Neurology, 48(Suppl. 3), III/22-III/27.
231. Wolters, E. C., & Berendse, H. W. (2001). Management of psychosis in Parkinson's disease. Current Opinion in Neurology, 14, 499-504.
232. Wright Willis, A., Evanoff, B. A., Lian, M., Criswell, S. R., & Racette, B. A. (2010). Geographic and ethnic variation in Parkinson disease: A population-based study of US Medicare beneficiaries. Neuroepidemiology, 34(3), 143-151. doi:10:1159/000275491
233. Zahodne, L. B., & Fernandez, H. H. (2008). A review of the pathophysiology and treatment of psychosis in Parkinson's disease. Drugs & Aging, 25(8), 665-682.
234. Zesiewicz, T. A., Sullivan, K. L., & Hauser, R. A. (2006). Nonmotor symptoms of Parkinson's disease. Expert Review of Neurotherapeutics, 6(12), 1811-1822.
235. Zoldan, J., Friedberg, G., Livneh, M., & Melamed, E. (1995). Psychosis in advanced Parkinson's disease: Treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology, 45(7), 1305-1308.
236. Zoldan, J., Friedberg, G., Weizman, A., & Melamed, E. (1996). Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson's disease. Advances in Neurology, 69, 541-544.